Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Zymeworks Inc. ZYME

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
4.67
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — 1 7 — — — — — — — —
Insider Ownership
5.58%

Capital & Financial Ratios

Market Cap
1,970.00
Revenue
37.13
Net Income
(149.99)
Free Cash Flow
(120.54)
Net Debt
(270.70)
Current Ratio
6.32
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
52.24
P/B ratio
24.13
Past 5Y EPS Growth
15.81%
This Y EPS Growth
228.09%
Next Y EPS Growth
(17.80%)
Next 5Y EPS Growth
69.06%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 374.33 225.78 228.80 270.70
Receivables 19.48 55.82 4.64 5.93
Inventory — — — —
Other — — — —
412.93 300.45 248.77 298.39
2023 2024 2025 Q'26
Payables 45.99 59.84 36.35 27.46
ST’ Debt — — — —
Other 0.96 — — —
55.76 88.29 42.32 47.24
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 2.41 4.59 — —
—
’25 27.11 48.73 27.61 2.52
105.97
’24 10.03 19.24 16.00 31.03
76.30
’23 35.58 7.00 16.51 16.93
76.01
’22 1.92 5.44 2.63 402.49
412.48
’21 0.64 1.77 4.40 19.87
26.68
’20 8.27 12.36 2.64 15.68
38.95
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (45.72) (31.95) — —
—
’25 (3.41) 12.07 (31.41) (10.26)
(33.00)
’24 (37.67) (24.99) (5.88) (41.51)
(110.06)
’23 (83.19) (6.40) (42.67) 13.95
(118.30)
’22 (55.41) (54.82) (73.01) 327.36
144.11
’21 (40.80) (50.35) (50.79) (50.51)
(192.45)
’20 (37.49) (49.96) (16.06) (47.90)
(151.40)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (45.93) (31.95) — —
—
’25 (3.74) 11.19 (31.82) (10.98)
(35.36)
’24 (38.33) (26.09) (6.88) (41.82)
(113.12)
’23 (83.58) (7.20) (43.80) 12.20
(122.38)
’22 (60.12) (58.57) (76.81) 326.48
130.98
’21 (41.50) (52.14) (55.96) (56.13)
(205.74)
’20 (38.44) (51.61) (18.69) (48.93)
(157.67)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.59) (0.62) — —
—
’25 (0.30) 0.03 (0.26) (0.55)
(1.08)
’24 (0.42) (0.49) (0.39) (0.31)
(1.62)
’23 (0.37) (0.76) (0.41) (0.20)
(1.72)
’22 (1.19) (0.97) (0.72) 4.65
1.90
’21 (0.87) (1.31) (1.25) (0.95)
(4.61)
’20 (0.64) (0.77) (1.43) (0.74)
(3.58)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 4.11 6.02 7.97 9.03 — — —
Low Price
— ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.27 10.99 17.70 28.49 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 294 277 286 264 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.40 0.27 0.27 0.40 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 412.48 76.01 76.30 105.97 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 49.43% (88.94%) (76.43%) (29.29%) — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 135.23 (119.24) (116.61) (79.75) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 32.79% (156.87%) (152.82%) (75.26%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 124.34 (118.67) (122.69) (81.13) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.24 17.31 11.19 11.11 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.33 1.10 1.01 1.41 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.91 (1.72) (1.62) (1.08) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.21 (1.72) (1.45) (0.44) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.20) (0.06) (0.04) (0.03) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.01 (1.78) (1.49) (0.47) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.56 6.75 4.47 3.56 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 65.20 68.86 75.85 75.41 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 4.24 0.00 0.00 0.00 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.19 9.40 14.55 18.74 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.00 1.54 3.28 7.39 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.07 4.83 11.94 16.62 ‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.21 (2.92) (8.05) (49.80) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 144.11 (118.30) (110.06) (33.00) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (13.12) (4.08) (3.07) (2.35) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 130.98 (122.38) (113.12) (35.36) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 449.08 357.16 212.16 206.45 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.13 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (464.10) (374.33) (225.78) (228.80) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 492.96 464.81 338.77 268.50 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.96% (19.30%) (23.51%) (20.04%) ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ 282.74% (95.36%) (75.84%) (145.69%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.51% (24.78%) (30.54%) (26.72%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Zymeworks Inc. (ZYME), a clinical-stage biotech developing multifunctional antibody therapies for cancer, exemplifies the sector’s high volatility, with revenue surges from milestone payments—like the 682% jump to $412 million in 2022 from zanidatamab partnerships—giving way to sharp declines and persistent losses. Gross margins swing wildly from negative territory to brief peaks, underscoring operational strains, cash burn, and eroding shareholder equity (down 27% in 2024 to $339 million), while free cash flow per share remains deeply negative outside outlier years. Trading 33-130% below analyst targets amid stabilizing revenue-per-share, the stock offers apparent upside but mirrors biotech’s feast-or-famine economics.

Recent insider activity provides a rare bullish counterpoint: a key director amassed $26.1 million in shares (1.6 million+) in early 2025, dwarfing minimal executive sells, signaling conviction ahead of potential Phase 3 catalysts for zanidatamab in the HER2 market. Analysts forecast 61-110% revenue growth through 2026, flipping EPS positive at $0.54 in 2025, with contracting EV/sales multiples—if milestones deliver.

Yet downside risks loom large: trial failures, funding squeezes in a high-rate environment, negative ROE (-30.5%), and capital inefficiencies could exacerbate balance sheet pressures. While net cash offers a buffer, ZYME demands cautious positioning—perhaps 5-10% for aggressive portfolios—awaiting data inflection. Read the full analysis for deeper balance sheet scrutiny and historical parallels.

Read full commentary →

Zymeworks Inc. (ZYME) Latest News

News by impact score

Fine-tune

1 Sep

4 , 12:02 PM
Jazz Pharmaceuticals shares rise after updated overall survival results from a gastric cancer study demonstrate positive outcomes in a program partnered with Zymeworks. Positive survival data strengthens the partnered gastric cancer asset and supports Zymeworks' pipeline value and investor positioning.

26 Aug

4 , 12:29 PM
Jazz Pharmaceuticals secured FDA approval for expanded use of Ziihera in gastric cancer. FDA nod expands commercial reach for Zymeworks' lead drug Ziihera via Jazz partnership.

25 Aug

5 , 10:23 AM
U.S. FDA approves Ziihera (zanidatamab-hrii) with and without tislelizumab plus chemotherapy in first-line HER2+ advanced gastroesophageal adenocarcinoma. FDA approval of Ziihera for first-line HER2+ advanced gastroesophageal adenocarcinoma drives major revenue growth and market expansion for Zymeworks.

4 www.marketbeat.com, 8:02 PM
Jazz Pharmaceuticals launches Ziihera after FDA approval for HER2-positive gastroesophageal adenocarcinoma, advancing commercialization of the therapy developed via Zymeworks partnership. FDA approval and launch of Ziihera drives major revenue upside for Zymeworks through its Jazz collaboration on the asset.

4 www.biopharmadive.com, 1:21 PM
FDA approves Jazz cancer drug with blockbuster sales potential, advancing Zymeworks partnered asset and revenue outlook. Approval unlocks major revenue stream for Zymeworks via licensing agreement.

4 stocktwits.com, 12:26 PM
FDA approves gastroesophageal cancer therapy, placing Zymeworks Inc. (ZYME), Jazz Pharmaceuticals, and related stocks in focus. FDA approval of cancer therapy marks major regulatory success for ZYME with direct effects on its portfolio and market trajectory.

24 Aug

4 investorshub.advfn.com, 6:48 AM
Zymeworks shares are rising ahead of a key FDA decision on Zanidatamab. FDA decision on Zanidatamab is a major regulatory event likely to significantly alter Zymeworks trajectory and investor sentiment.

11 Aug

4 , 9:30 AM
TBPH met Q2 earnings estimates and is to be acquired by Zymeworks. Acquisition of TBPH constitutes a major strategic move that will significantly reshape Zymeworks' operations and market position.

6 Aug

3 , 4:05 PM
Zymeworks Inc. released second quarter 2026 financial results and a corporate update. Quarterly results and updates directly shape near-term investor views on financial position and pipeline progress.

3 Aug

3 www.marketbeat.com, 6:03 PM
Jazz Pharmaceuticals Q2 earnings call highlighted progress on its zanidatamab collaboration with Zymeworks, including clinical trial updates and regulatory milestones. Partner earnings call updates on shared pipeline assets can moderately affect ZYME development timelines and investor views.

30 Jun

5 , 8:54 AM
Zymeworks announces buyout, triggering 3% drop in Theravance stock price. Buyout announcement triggers immediate ownership change and revalues entire Zymeworks equity.

4 www.pharmaceutical-technology.com, 4:26 AM
Zymeworks agrees to acquire Theravance Biopharma for $929 million. The $929 million acquisition marks a major strategic expansion for Zymeworks.

29 Jun

4 stocktwits.com, 8:44 AM
Zymeworks acquires Theravance Biopharma in a $929M deal with analysis of effects on TBPH shareholders. Zymeworks $929M acquisition of Theravance Biopharma marks major strategic expansion likely to reshape company trajectory.

4 , 8:39 AM
Zymeworks agreed to acquire Theravance for a lung disease drug, triggering share price declines for both companies. Acquisition of Theravance lung disease drug marks major strategic expansion with potential to alter company trajectory.

4 , 7:26 AM
Zymeworks Inc. stock declines after securing a $929 million buyout lifeline. $929 million buyout delivers major capital infusion that shifts Zymeworks financial position and investor outlook.

4 , 6:19 AM
Zymeworks Inc. agrees to acquire Theravance Biopharma in a $929 million deal. Acquisition of Theravance Biopharma for $929 million marks major strategic expansion of Zymeworks pipeline and operations.

4 , 6:00 AM
Zymeworks Inc. enters into definitive agreement to acquire Theravance Biopharma for $17.00 per share in cash plus a contingent value right. Acquisition of Theravance Biopharma marks major strategic expansion likely to significantly alter Zymeworks trajectory and investor sentiment.

4 , 6:00 AM
Zymeworks acquires Theravance Biopharma. Acquisition constitutes major strategic move that can significantly alter Zymeworks trajectory and investor sentiment.

18 Jun

3 , 8:00 AM
Gandeeva collaborates with Zymeworks to apply Cryo-EM technology for faster antibody drug discovery. Partnership applies Cryo-EM imaging to accelerate Zymeworks antibody development and pipeline efficiency.

3 , 8:00 AM
Gandeeva and Zymeworks apply Cryo-EM technology to accelerate antibody drug discovery. Cryo-EM partnership strengthens Zymeworks antibody discovery pipeline and R&D speed.

14 Jun

3 , 6:05 PM
Zymeworks presented new Phase 1 data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026. Phase 1 data release for ZW191 marks early clinical progress that can moderately affect investor sentiment and pipeline perception.

14 May

4 GlobeNewswire, 4:05 PM
Zymeworks Inc. (ZYME) announced a share repurchase program authorizing the company to buy back up to $125 million of its common stock. A $125 million share repurchase signals management confidence and can significantly boost stock price and investor sentiment by reducing outstanding shares.

11 May

3 Simply Wall St., 8:32 AM
Analysts forecast Zymeworks Inc. (NASDAQ:ZYME) performance after its first-quarter results. Analyst forecasts following Q1 results may moderately influence Zymeworks' financial expectations and market sentiment.

9 May

4 Simply Wall St., 5:24 PM
Zymeworks Inc. (ZYME) missed earnings expectations amid key FDA updates and capital return announcements, prompting a fresh valuation assessment. Earnings miss, FDA updates, and capital return initiatives signal major shifts in financial health, regulatory progress, and shareholder value that could reshape ZYME's market trajectory.

3 www.marketbeat.com, 5:05 AM
Zymeworks Inc. reported Q1 financial results including revenue from milestones and royalties, narrowed net loss, strong cash position of $340 million, progress in Azymeworks platform with IND filing for ZW191, positive ZW49 data, and maintained full-year cash runway guidance. Q1 financials and clinical pipeline updates signal moderate operational progress amid biotech volatility, balancing investor sentiment without transformative shifts.

8 May

4 app.moby.co, 8:30 AM
Zymeworks Inc. (ZYME) released Q1 2026 earnings call summary covering financial results, pipeline updates, and forward guidance. Q1 2026 earnings call reveals financial performance, clinical progress, and strategic outlook directly shaping Zymeworks' trajectory and investor confidence.

7 May

4 GlobeNewswire, 4:05 PM
Zymeworks Inc. (ZYME) provided a corporate update and reported first quarter 2026 financial results. Quarterly financial results and corporate updates directly affect Zymeworks' financial health, pipeline progress, and investor sentiment.

3 , 7:05 PM
Zymeworks Inc. (ZYME) reported a Q1 net loss and missed revenue estimates. Q1 loss and revenue shortfall indicate weaker financial performance, likely affecting short-term market sentiment and stock price.

6 May

3 www.marketbeat.com, 4:42 PM
Royalty Pharma's Q1 earnings call highlights updates on Zymeworks Inc. (ZYME) royalties, including ongoing payments from zanidatamab and pipeline advancements, signaling steady revenue stream amid clinical progress. Royalty Pharma's highlights on Zymeworks royalties indicate moderate financial and pipeline impacts influencing market sentiment.

26 Apr

4 www.marketbeat.com, 3:12 AM
Zymeworks Inc. showcased royalty-fueled strategic pivot at Bloom Burton conference, targeting multibillion-dollar Ziihera opportunity. Royalty-driven pivot and multibillion-dollar Ziihera pursuit represent major strategic shift boosting long-term revenue potential and investor interest.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us